

Substitute for Form 1449 A & B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

5

Application Number	10/643,384
Confirmation Number	4836
Filing Date	August 19, 2003
First Named Inventor	Kenneth A. BRASEL et al
Art Unit	1644
Examiner Name	Phillip GAMBEL
Attorney Docket Number	A9169

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
PG		US 5,627,025		05/06/1997	Steinman et al
		US 5,635,388		06/03/1997	Bennet et al
		US 5,554,512		09/10/1996	Lyman et al
		US 6,017,544		01/2000	Srivastava et al
		US 5,626,862		05/1997	Brem et al
		US 5,116,964		05/26/1992	Capon et al
		US 5,185,438		02/09/1993	Lemischka et al
		US 5,192,553		03/09/1993	Boyse et al

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		EP	0 627 487		05/19/1994	Lyman et al	
		WO	92/18615		10/29/1992		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Sprecher et al, <i>Arch. Virol.</i> , 132(1-2):1-28 (1983)	
		Debets et al, <i>Immunol. Today</i> , 15(10):445-458 (1994)	
		Broxmeyer et al, <i>Exp. Hematol.</i> , 23(10):1121-1129 (1995)	
		Porgador et al, <i>J. Exp. Med.</i> , 182(1):255-260 (1995)	
		Lotem et al, <i>Leukemia</i> , 2(12 Supplemental):24S-37S (1988)	
		Bernhard et al, <i>Cancer. Res.</i> , 55:1099-1104 (1995)	
		Chatterjee et al, <i>Cancer Immunol. Immunotherap.</i> , 38:75-82 (1994)	
		Boon et al, <i>Adv. Cancer Res.</i> , 58:177-210 (1992)	
		McBride, <i>J. National Cancer Inst.</i> , 89(1):1257 (1997)	
		Pulendran et al, <i>J. Immunol.</i> , 159(5):2222-2231 (1997)	
		Shurin et al, <i>Cell Immunol.</i> , 179(2):174-184 (1997)	
		Chen et al, <i>Cancer Res.</i> , 57(16):3511-3516 (1997)	
		Strobl et al, <i>Blood</i> , 90(4):1425-1434 (1997)	
		Juan et al, <i>Blood</i> , 90(1):76-84 (1997)	
		Lynch et al, <i>Nature Med.</i> , 3(6):625-631 (1997)	
		Saunders et al, <i>J. Exp. Med.</i> , 184(6):2185-2196 (1996)	
		Maraskovsky et al, <i>J. Exp. Med.</i> , 184(5):1953-1962 (1996)	
		Skolnick et al, <i>Trends in Biotech.</i> , 18(1):34-39 (2000)	
		Shaw et al, <i>J. Immunol.</i> , 161(6):2817-2824 (1998)	

Examiner Signature

Phillip Gambel 4/20/07

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/643,384
				Confirmation Number	4836
				Filing Date	August 19, 2003
				First Named Inventor	Kenneth A. BRASEL et al
				Art Unit	1644
				Examiner Name	Phillip GAMBEL
Sheet	2	of	5	Attorney Docket Number	A9169

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 4,745,099		05/17/1988	Akamatsu et al
		US 5,013,824		05/07/1991	Abrams et al
		US 5,057,420		10/15/1991	Massey
		US 5,061,620		10/29/1991	Tsukamoto et al
		US 5,114,710		05/19/1992	Takaku et al
		US 5,199,942		04/06/1993	Gillis
		US 5,270,458		12/14/1993	Lemischka
		US 5,283,354		02/01/1994	Lemischka
		US 5,326,558		07/05/1994	Turner et al
		US 5,367,057		11/22/1994	Lemischka
		US 5,397,706		03/14/1995	Correa et al
		US 5,399,493		03/21/1995	Emerson et al
		US 5,437,994		08/01/1995	Emerson et al
		US 5,453,357		09/26/1995	Hogan
		US 5,459,069		10/17/1995	Palsson et al
		US 5,525,708		06/11/1996	Nocka et al
		US 5,548,065		08/20/1996	Lemischka
		US 5,843,423		12/01/1998	Lyman et al

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	93/08268		04/29/1993		
		CA	2,163,105		05/18/1994		
		WO	94/26891		11/24/1994		
		WO	94/28391		12/08/1994		
		WO	95/00554		01/05/1995		
		WO	93/20186		10/14/1993		
		EP	0 563 485		03/30/1992		
		WO	96/00779		01/11/1996		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Flanagan et al, <i>Cell</i> , 63:185-194 (1990)	
		Cadena et al, <i>FASEB</i> , 6:2332-2337 (1992)	
		Matthews et al, <i>Cell</i> , 65:1143-1152 (1991)	
		Lyman et al, <i>OncoGene</i> , 8:815-822 (1993)	
		Rosnet et al, <i>Genomics</i> , 9:380-385 (1991)	
		Lyman et al, <i>Cell</i> , 75:1157-1167 (1993)	

Examiner Signature		Date Considered	4/30/07
--------------------	--	-----------------	---------



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/643,384
				Confirmation Number	4836
				Filing Date	August 19, 2003
				First Named Inventor	Kenneth A. BRASEL et al
				Art Unit	1644
				Examiner Name	Phillip GAMBEL
Sheet	3	of	5	Attorney Docket Number	A9169

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶	
		Maroc et al, <i>Oncogene</i> , 8:909-918 (1993)		
		Birg et al, <i>Blood</i> , 80(10): 2584-2593 (1992)		
		Dosil et al, <i>Mol. and Cell Biol.</i> , 13(10):6572-6585 (1993)		
		Hannum et al, <i>Nature</i> , 368:643-648 (1994)		
		Broxmeyer et al, <i>Blood Cells</i> , 20:492-497 (1994)		
		de Vries et al, <i>J. of Cell. Biochem., Suppl.</i> 18b:177 (Abstract #H110) (1994)		
		Rossner et al, <i>Cell Growth & Differentiation</i> , 5:549-555 (1994)		
		Small et al, <i>Proc. Acad. Natl. Acad. Sci. USA</i> , 91:459-463 (1994)		
		Zeigler et al, <i>Blood</i> , 84(8):2422-2430 (1994)		
		de Vries et al, <i>Blood</i> , 84(10):Suppl. 1:279a (Abstract #1100) (1994)		
		de Vries et al, <i>Experimental Hematology</i> , 22(8):724 (Abstract #174) (1994)		
		Stewart et al, <i>Blood</i> , 81(9):2283-2289 (1993)		
		Hudak et al, <i>Blood</i> , 85(10):2747-2755 (1995)		
		Muench et al, <i>Blood</i> , 85(4):963-972 (1995)		
		Steinman et al, <i>Annu. Rev. Immunol.</i> , 9:271-296 (1991)		
		Macatonia et al, <i>Immunology</i> , 74:399-406 (1991)		
		Pancholi et al, <i>Immunology</i> , 76:217-224 (1992)		
		Inaba et al, <i>J. Exp. Med.</i> , 172:631-340 (1990)		
		Bujdoso et al, <i>Intern. Rev. Immunol.</i> , 6:177-186 (1990)		
		Jaffe et al, <i>Pediatric Pathology</i> , 13:821-837 (1993)		
		Bernstein et al, <i>Blood Cells</i> , 20:15-24 (1994)		
		Young et al, <i>J. Exp. Med.</i> , 182:1111-1120 (1995)		
		Inaba et al, <i>J. Exp. Med.</i> , 178:479-488 (1993)		
		Papayannopoulo et al, <i>Blood</i> , 90:620-329 (1997)		
			Stewart et al, <i>Blood</i> , 83(10):2975-2801 (1994)	
			Hanahan et al, <i>Science</i> , 246:1265-1275 (1989)	
			Romani et al, <i>J. Exp. Med.</i> , 180:83-93 (1994)	

Examiner Signature		Date Considered	4/30/07
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/643,384
				Confirmation Number	4836
				Filing Date	August 19, 2003
				First Named Inventor	Kenneth A. BRASEL et al
				Art Unit	1644
				Examiner Name	Phillip GAMBEL
Sheet	4	of	5	Attorney Docket Number	A9169

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Winton et al, "Recombinant Human (rh) FLT3 Ligand Plus rhGM-CSF or rhG-CSF Causes a Marked CD34 ⁺ Cell Mobilization to Blood in Rhesus Monkeys", ASH Abstract (December 1996)	
		Sallusto et al, <i>J. Exp. Med.</i> , 179:1109-1118 (1994)	
		Szabolics et al, <i>J. Immunol.</i> , 154:5851-5861 (1995)	
		Rosnet et al, <i>Oncogene</i> , 6:1641-1650 (1991)	
		Stengelin et al, <i>EMBO J.</i> , 7(4):1053-1059 (1998)	
		Small et al, <i>Blood</i> , 80:296a (Abstract No. 1174 (1992)	
		Reid et al, <i>J. of Immunol.</i> , 149(8):2681-2688 (1992)	
		Thomson et al, <i>Stem Cells</i> , 13:622-639 (1995)	
		Lyman et al, <i>Blood</i> , 91(4):1101-1134 (1998)	
		Ray et al, "Flt3 Ligand Supports the Differentiation of Early B Cell Progenitors in the Presence of IL-11 and IL-7", Manuscript (February 20, 1996)	
		Chklovskaja et al, "Increased Production of FLT3 Ligand in Leukemia Patients with Chemotherapy-Included Bone Marrow Suppression", 1996 EHA Abstract Form, Second Meeting of the European Haematology Association (May 29-June 1, 1996)	
		Wodnar-Flipiowicz et al, "Tyrosine kinase receptors and their ligands in aplastic anemia", Manuscript (February 20, 1996)	
		Hsu et al, "Antigen-Pulsed Dendritic Cells in the Treatment of Patients with B-cell Lymphoma", Abstract #C1-314, Keystone Conference, Taos, New Mexico (March 1995)	
		Drexhage et al, "A Defective Maturation and Function of Dendritic Cells in Type I Diabetes", Abstract #C1-204, Keystone Conference, Taos, New Mexico (March 1995)	
		Fisch et al, "Ex Vivo Generation of Functionally Active Antigen Presenting Cell From Peripheral Blood CD34 ⁺ Hematopoietic Progenitor Cells in Cancer Patients", Abstract #C1-311, Keystone Conference, Taos, New Mexico (March 1995)	
	Mayordomo et al, "Bone Marrow-Derived Dendritic Cells Serve as Potent Adjuvants for Peptide-Based Anti-tumor Vaccines", Abstract #C1-213, Keystone Conference, Taos, New Mexico (March 1995)		
	Lenz et al, "MHC-Class I ⁺ /II ⁺ Dendritic Cells Sensitize for Transplantation Immunity", Abstract #C1-318, Keystone Conference, Taos, New Mexico (March 1995)		
	Ye et al, "Evaluation of Dendritic Cells in Allogeneic Marrow Grafts", Abstract #C1-130, Keystone Conference, Taos, New Mexico (March 1995)		

Examiner Signature		Date Considered	4/25/07
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/643,384		
		Confirmation Number	4836		
		Filing Date	August 19, 2003		
		First Named Inventor	Kenneth A. BRASEL et al		
		Art Unit	1644		
		Examiner Name	Phillip GAMBEL		
Sheet	5	of	5	Attorney Docket Number	A9169

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
M		Thomson et al, "Growth of Donor-Derived Dendritic Cells from the Bone Marrow of Murine Liver Allograft Recipients in Response to Granulocyte/Macrophage Colony-Stimulating Factor", Abstract #C1-125, Keystone Conference, Taos, New Mexico (March 1995)	
W		Whalen et al, "DNA-Mediated Immunization to the Hepatitis B Surface Antigen: Potential Involvement Of Interstitial Dendritic Cells", Abstract #C1-128, Keystone Conference, Taos, New Mexico (March 1995)	
W		Alters et al, "Characterization and Gene Modification of Dendritic Cells to be Used for Antigen Presentation", Abstract #C1-302, Keystone Conference, Taos, New Mexico (March 1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Phillip Gambel
4/22/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Docket No: A-9169

Kenneth A. BRASEL et al

Conf. No.: 4836

Appln. No.: 10/643,384

Group Art Unit: 1644

Filed: August 19, 2003

Examiner: Gambel, P.

For: USE OF FLT3-LIGAND IN THE TREATMENT OF INFECTION

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97 and 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

02/07/2007 BABRAHA1 00000029 10643384
01 FC:1806 180.00 DP

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form which are all the references of record in parent application Nos. 10/241,927; 09/444,027; 09/154,903; 08/725,540; 08/539,142. Each of the listed documents was cited in the parent applications. Applicants are not submitting duplicate copies of these references, but request that they be considered and listed on the face of any patent granted on the above application (see 37 C.F.R. §1.98(d)).

The present Information Disclosure Statement is being filed (without a Statement Under 37 C.F.R § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits. Therefore a check for the fee, in the amount of \$180.00 (under 37 C.F.R. § 1.17(p)) is attached.